# The Type VI secretion system in enteric pathogen colonization: molecular mechanisms, ecological dynamics, and therapeutic potential

## TL;DR

This paper explores how the Type VI Secretion System helps gut pathogens outcompete other microbes and harm host cells, offering new ways to develop targeted antimicrobial treatments.

## Contribution

The study reveals the T6SS's role in both bacterial warfare and nutrient acquisition, along with its regulation by gut conditions.

## Key findings

- T6SS allows pathogens to kill commensal bacteria and disrupt colonization resistance.
- The system aids in acquiring micronutrients like iron and zinc through exploitative competition.
- T6SS manipulates host cells and is regulated by gut signals like bile salts and pH.

## Abstract

The Type VI Secretion System (T6SS) is a sophisticated, phage-tail-like contractile nanomachine that mediates contact-dependent protein translocation in a wide range of Gram-negative enteric pathogens. As a primary weapon for interference competition, T6SS enables pathogens like Salmonella and Vibrio cholerae to directly eliminate commensal rivals. This targeted elimination allows pathogens to dismantle microbiota-mediated colonization resistance and seize essential nutritional niches. Beyond interbacterial warfare, the system facilitates “exploitative competition” by secreting effectors for the acquisition of limited micronutrients such as iron and zinc. Furthermore, T6SS acts as a crucial virulence determinant by manipulating host cell signaling, disrupting cytoskeletal integrity, and even enhancing intestinal contractions to physically expel competitors. The expression and activity of T6SS are dynamically regulated by gastrointestinal cues, including bile salts, pH fluctuations, and quorum sensing signals, ensuring its activation is precisely timed during infection. Elucidating these multifaceted roles not only deepens our understanding of microbial ecology in the gut but also highlights T6SS as a promising target for microbiome engineering and the development of customizable, precision antimicrobial therapies.